Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Francesco Facchinetti
ResearcherPublications, citations & collaboration network
Francesco Facchinetti is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 319 works, 4,030 citations, an h-index of 35 and an i10-index of 73.
319
Works
4,030
Citations
35
h-index
73
i10-index
How has Francesco Facchinetti's publication output changed over time?
ScholarIQpublication output · 2016–2024
Output grew0% over the shown period — from 1 works in 2016 to 1 in 2024.
1
1
3
2
1
1
1
2016201720182019202020222024
What are the most-cited papers on Francesco Facchinetti?
ScholarIQmost cited works
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Gonzalo Recondo, Francesco Facchinetti, Ken A. Olaussen, Benjamin Besse, Luc Friboulet
S41981144. 2018331 Citations
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z. Rizvi, Rosa L. Frias, Jean Paul Thiery, Jean‐Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Déas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Brayé, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hollebecque, Claudio Nicotra, Maud Ngo‐Camus, Stefan Michiels, Ludovic Lacroix, Catherine Richon, Nathalie Auger, Thierry de Baère, Lambros Tselikas, Éric Solary, Eric Angevin, Alexander Eggermont, Fabrice André, Christophe Massard, Ken A. Olaussen, Jean‐Charles Soria, Benjamin Besse, Luc Friboulet
Clinical Cancer Research. 2019169 CitationsOPEN ACCESS
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Alessandro Leonetti, Francesco Facchinetti, Giulio Rossi, Roberta Minari, Antonia Conti, Luc Friboulet, Marcello Tiseo, David Planchard
S49831067. 2018167 Citations
Transferrin receptor targeting chimeras for membrane protein degradation
Dingpeng Zhang, Jhoely Duque-Jimenez, Francesco Facchinetti, Garyk Brixi, Kaitlin Rhee, William W. Feng, Pasi A. Jänne, Xin Zhou
Nature. 2024159 CitationsOPEN ACCESS
Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remón, Jean‐Yves Scoazec, Fabrice André, Jean‐Charles Soria, Luc Friboulet
Clinical Cancer Research. 2016151 Citations
Related on ScholarIQ
Dana-Farber Cancer Institute
Institution
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Paper
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Paper
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Paper
Transferrin receptor targeting chimeras for membrane protein degradation
Paper
Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers
Paper